Dynamic cytogenetic evolution in multiple myeloma: prognostic implications from diagnosis to first relapse
The Oncologist · 10.04.2026 · 31 (5)
DOI: 10.1093/oncolo/oyag105 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 23.03.2026. Verfasst von Qi Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Chromosome Aberrations, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Cytogenetic abnormalities (CAs) in multiple myeloma (MM) are traditionally assessed statically at diagnosis, but longitudinal monitoring reveals dynamic clonal evolution, particularly during relapse. In Asian populations, data on CA dynamics and their prognostic impact remain scarce. Patients and Methods This retrospective study included 106 MM patients (2014-2024) in whom CAs were evaluated at diagnosis and relapse via cIg-FISH. The prognostic impact of clonal burden, copy number alterations, and longitudinal evolution of cytogenetic complexity was comprehensively assessed.
Results
At first relapse, 33.0% of patients acquired new CAs, with 1q21+ and del(17p13) incidences significantly increasing (P = .032, P = .003). Longitudinal analysis showed 1q21 amplification (≥4 copies) expanded (27.4%-40.6%), while gain (3 copies) remained stable. Baseline 1q21 amplification predicted shorter 1st PFS (P = .002), whereas 1q21 gain at relapse correlated with inferior 2nd PFS (P = .023), often co-occurring with del(17p13) (28.1%). Persistent 1q21+ and de novo del(17p13) both predicted inferior OS (P < .05). Based on clonal dynamics, patients with >20% expansion exhibited significantly shorter 1st PFS (P = .045) compared to the stable (unchanged) CAs subgroup. Similarly, those acquiring new CAs had shorter 2nd PFS (P = .039) and a trend toward worse OS (P = .056).
Conclusion
Both acquisition of new CAs and expansion of existing clones at relapse are key prognostic indicators, highlighting the importance of dynamic CA monitoring in MM management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
- The First School of Clinical Medicine, Nanjing Medical University, Nanjing 211166, China.
ORCID-Profile: Lijuan Chen, Rui Guo
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, Q., Tian, T., Shi, Y., Shen, X., Qiu, H., Jin, Y., Chen, L., & Guo, R. (2026). Dynamic cytogenetic evolution in multiple myeloma: prognostic implications from diagnosis to first relapse. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag105
Vancouver
Chen Q, Tian T, Shi Y, Shen X, Qiu H, Jin Y, et al. Dynamic cytogenetic evolution in multiple myeloma: prognostic implications from diagnosis to first relapse. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag105
BibTeX
@article{Chen2026,
author = {Chen, Qi and Tian, Tian and Shi, Yu and Shen, Xuxing and Qiu, Hairong and Jin, Yuanyuan and Chen, Lijuan and Guo, Rui},
title = {Dynamic cytogenetic evolution in multiple myeloma: prognostic implications from diagnosis to first relapse},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {5},
doi = {10.1093/oncolo/oyag105}
}
EUVIMED